Market Place
Sourcing Support
Areteia Therapeutics Announces Additional $75MM in Series A Financing
13 Feb 2024 //
BUSINESSWIRE
Areteia Therapeutics Announces Publication of PII Data of Oral Dexpramipexole
03 Aug 2023 //
BUSINESSWIRE
Areteia Announces Start of Phase III Trials of Oral Dexpramipexole
09 Mar 2023 //
BUSINESSWIRE
Bain leads $350M bet on oral asthma startup to fund phase 3
12 Jul 2022 //
FIERCEBIOTECH
Knopp Bio Presents New Phase 2 Data at AAAAI 2022 on Oral Dexpramipexole
28 Feb 2022 //
BUSINESSWIRE
Knopp Biosciences Announces Positive Results from the Phase 2 EXHALE Trial
08 Sep 2021 //
BUSINESSWIRE
Knopp Biosciences Presents New Phase 2 Data at ERS 2021
07 Sep 2021 //
BUSINESSWIRE
Knopp meldet positive Top-Line-Ergebnisse aus der Ph-2-Studie EXHALE
14 Jan 2021 //
BUSINESSWIRE
Knopp Biosciences to begin Trial of Oral Dexpramipexole in Eosinophilic Asthma
16 Sep 2020 //
GLOBENEWSWIRE
Can Biogen rebound in ALS? Maybe so, new antisense data suggest
09 Jul 2020 //
FIERCE BIOTECH
Knopp & University of Leicester Update ph2 Trial of Oral Dexpramipexole
02 Dec 2019 //
BUSINESS WIRE
Knopp begins study of dexpramipexole in eosinophilic asthma patients
20 Aug 2019 //
CLINICALTRIAL SARENA
Knopp Biosciences Announces Start of Ph2 Clinical Evaluating Oral Dexpramipexole
19 Aug 2019 //
BUSINESSWIRE
Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole
24 Apr 2019 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.